Predict your next investment

Diurnal company logo
HEALTHCARE | Drug Development
diurnal.co.uk

See what CB Insights has to offer

Founded Year

2004

Stage

Seed VC - II | Alive

Total Raised

$1.53M

Last Raised

$530K | 9 yrs ago

About Diurnal

Diurnal is a pharmaceutical company that creates hormone therapeutics using formulations and physiological treatment regimes of approved drugs. The company addresses the unmet clinical and patient needs for hormone replacement treatments by creating more effective products for life-long treatment for the chronic conditions: adrenal insufficiency, rheumatoid arthritis, hypogonadism, and hypothryroidism. Diurnal's approach in utilizing only drugs that have been approved and with a well established safety and efficacy profile enables it to judiciously focus on optimizing therapeutic performance principally by altering the drug delivery modality and treatment regimes. This approach also enables Diurnal to de-risk the development program and avoid the need for the substantial and costly commitment to pre-clinical development prior to proof-of-concept evaluation.

Diurnal Headquarter Location

8th Floor, Eastgate House 35-43 Newport Road

CF24 0AB,

United Kingdom

+44 (0)871 716 8848

Latest Diurnal News

Diurnal Group plc - Results for the year ended 30 June 2021

Sep 14, 2021

Alkindi® growth of 18% in core markets despite continued impact of Covid-19 on hospital visits Post-period, launch of Efmody® in Europe, Diurnal's second product on the market following Alkindi® Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces its audited results for the year ended 30 June 2021. Operational highlights (including post-period): Alkindi® (hydrocortisone granules in capsules for opening) Continued rollout of Alkindi® across Europe with growth in UK, Germany and Italy, despite the impact of Covid-19 on patients' ability to visit hospitals and physicians' ability to switch patients to Alkindi®. Alkindi Sprinkle® approved by the US Food and Drug Administration (FDA) and subsequent launch in the US by Eton Pharmaceuticals (Eton) in November 2020. Signed distribution agreements to expand the future availability of Alkindi® in Benelux, Switzerland, Turkey and China. Further Alkindi® regulatory approvals in Australia and Israel. Efmody® (modified-release hydrocortisone) Approval of Efmody® as treatment of congenital adrenal hyperplasia (CAH) in adults and adolescents aged 12 years and over. Efmody® commercial roll-out initiated in September 2021 with launches in Germany, Austria and Great Britain. Successful completion of Special Protocol Assessment (SPA) with the FDA for the pivotal Efmody® US Phase 3 study in CAH; study due to commence in Q4 2021. Publication of Efmody® European Phase 3 pivotal trial and extension study data in the Journal of Clinical Endocrinology and Metabolism (JCEM). Signed further distribution agreements for Efmody® in Benelux, Nordic countries, Turkey, Romania, and Bulgaria. Development products: DITEST™ (native oral testosterone formulation) Positive meeting with the FDA confirming abbreviated 505(b)(2) development pathway, with potential to be the first effective oral native testosterone treatment in an estimated $5.0bn global market. Financial overview Total revenues for the year were £4,371k (2020: £6,313k), comprising Alkindi® product sales of £2,267k (2020: £2,390k) and licensing income of £2,104k (2020: £3,923k), with lower Alkindi® product sales predominantly due to lower sales to the Company's Nordic distribution partner. Continued growth of Alkindi® sales in core commercial markets of the UK, Germany, Italy and Austria, with proforma sales increasing by 18% in these countries despite the impact of the Covid-19 pandemic. Operating loss for the year was £11,600k (2020: £5,392k), reflecting pre-launch commercialisation expenditure for Efmody® and the increase in Research and Development (R&D) expenditure for the set-up costs of upcoming key studies for Efmody® and DITEST™. Cash and cash equivalents were £34,037k (2020: £15,434k), reflecting the completion of two oversubscribed Placing and Open Offers during the year, raising a total of £28,762k after expenses, to open up new markets and indications for Efmody® and to further develop DITEST™ and other early-stage pipeline opportunities. Diurnal expects its cash resources to take its core commercial European cortisol deficiency franchise through to profitability based upon current plans and assumptions, including expectations regarding the timing of product approvals and sales projections. Financial year end to be changed to 31 December, with next statutory reporting due for the 18 month period to 31 December 2022. Martin Whitaker, CEO of Diurnal, commented:   "Over the past year, Diurnal has continued to make significant progress in its ambition towards becoming a world-leading endocrinology company. We continued to roll-out Alkindi® across Europe and secured FDA approval for the product, which was subsequently launched in the US by our partner Eton. Another key milestone was the approval of our second product, Efmody®, in Europe. The launch is progressing well and  we expect to realise synergies in the utilisation of our existing European commercial infrastructure and supply chain from Alkindi® which we anticipate to lead to the rapid uptake of Efmody® as a new treatment option available for patients suffering from CAH as the launch gains momentum. "In our pipeline, we are excited to progress our development strategy for Efmody® in the US, as well as the clinical development of DITEST™, with an IND application expected to be filed later this year. We continue to believe that Diurnal is well positioned with sufficient cash resources to take our core commercial European cortisol deficiency franchise through to profitability and look forward to reporting on further operational and commercial progress in this current financial period." Martin Whitaker, Chief Executive Officer, and Richard Bungay, Chief Financial Officer, will provide a live presentation relating to the Company's financial results today via the Investor Meeting Company platform at 11:00 BST. The online presentation is open to all existing and potential shareholders. Investors can sign up to Investor Meet Company for free and interested parties can register to attend the presentation via the following link:  https://www.investormeetcompany.com/diurnal-group-plc/register-investor  . In the audited results for the year ended 30 June 2021: "bn", "m" and "k" represent billion, million and thousand, respectively  "Group" is the Company and its subsidiary undertakings, Diurnal Limited and Diurnal Europe B.V. This is a business press release containing financial information and/or data for the benefit of shareholders and potential investors. Data are included to allow informed investment decisions. For further information

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Diurnal

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Diurnal is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Diurnal Patents

Diurnal has filed 7 patents.

The 3 most popular patent topics include:

  • Adrenal gland disorders
  • Circadian rhythm
  • Diketones
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/5/2017

1/1/2019

Glucocorticoids, Pregnanes, Diketones, Fluoroarenes, Circadian rhythm

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/5/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

1/1/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Glucocorticoids, Pregnanes, Diketones, Fluoroarenes, Circadian rhythm

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Diurnal Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Diurnal Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.